Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IDEXX LABORATORIES, INC.

(IDXX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
558.65(c) 555.06(c) 554.63(c) 534.2(c) 529.35(c) Last
577 026 609 066 383 048 400 543 570 436 Volume
+1.52% -0.64% -0.08% -3.68% -0.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3 199 M - -
Net income 2021 725 M - -
Net Debt 2021 595 M - -
P/E ratio 2021 63,3x
Yield 2021 -
Sales 2022 3 544 M - -
Net income 2022 798 M - -
Net Debt 2022 305 M - -
P/E ratio 2022 57,1x
Yield 2022 -
Capitalization 44 885 M 44 885 M -
EV / Sales 2021 14,2x
EV / Sales 2022 12,8x
Nbr of Employees 9 300
Free-Float -
More Financials
Company
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the... 
More about the company
Ratings of IDEXX Laboratories, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about IDEXX LABORATORIES, INC.
01/14TRACKINSIGHT : Risk-takers bracing for Nasdaq 100 revival with leveraged ETF
TI
01/13One Health Company Collaborates with IDEXX to Expand Access to FidoCure« Precision Medi..
CI
01/13IDEXX Laboratories, PetDx Enter Dog Cancer Testing Collaboration
MT
01/13PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs
PR
01/13IDEXX Laboratories to Launch New Diagnostic Tests for Animal Cancer
MT
01/13IDEXX Innovative Diagnostic and Software Solutions Provide Workflow Efficiency and Fast..
PR
01/13IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enab..
CI
01/13IDEXX Enables Improved Cancer Diagnosis and Personalized Care through Expanded Oncology..
PR
01/11IDEXX Laboratories to Release 2021 Fourth Quarter and Full Year Financial Results
PR
2021IDEXX LABORATORIES INC /DE : Entry into a Material Definitive Agreement, Creation of a Dir..
AQ
2021INSIDER SELL : Idexx Laboratories
MT
2021ANALYST RECOMMENDATIONS : AbbVie, AIG, CBRE, Stoneco, Vonage...
2021Morgan Stanley Initiates IDEXX Laboratories at Overweight With $732 Price Target
MT
2021INSIDER SELL : Idexx Laboratories
MT
2021Israel suggests U.S open consulate for Palestinians in West Bank, not Jerusalem
RE
More news
News in other languages on IDEXX LABORATORIES, INC.
01/14TRACKINSIGHT : áLes preneurs de risques se préparent à la reprise du Nasdaq 100 avec des E..
01/13Une société de santé collabore avec IDEXX pour élargir l'accès à la plateforme de médec..
01/13IDEXX Laboratories et PetDx concluent une collaboration pour le dépistage du cancer che..
01/13IDEXX Laboratories, Inc. annonce une série d'améliorations de produits et de services q..
2021VENTE D'INITIÉS : Idexx Laboratories
More news
Analyst Recommendations on IDEXX LABORATORIES, INC.
More recommendations
Chart IDEXX LABORATORIES, INC.
Duration : Period :
IDEXX Laboratories, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDEXX LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 529,35 $
Average target price 648,29 $
Spread / Average Target 22,5%
EPS Revisions
Managers and Directors
Jonathan J. Mazelsky President, Chief Executive Officer & Director
Brian Patrick McKeon Chief Financial Officer, Treasurer & Executive VP
Lawrence D. Kingsley Non-Executive Chairman
Ken Grady Chief Information Officer & Senior VP
Jeffrey Thomas Chief Technology Officer & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
IDEXX LABORATORIES, INC.-19.61%44 885
ABBOTT LABORATORIES-8.94%219 790
MEDTRONIC PLC4.93%145 952
STRYKER CORPORATION-0.27%100 614
BECTON, DICKINSON AND COMPANY4.43%74 858
HOYA CORPORATION-10.96%49 369